Clinical Trial Update: Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 clinical trial investigated how plasma concentrations of hydroxyprogesterone caproate (17-OHPC) relate to preterm birth outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Preterm Birth

Drugs mentioned

• Hydroxyprogesterone caproate (hydroxyprogesterone caproate)

Snippet

Sponsor: Steve N. Caritis, MD | Conditions: Preterm Birth | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-10-23